Dr. Morrison, president of OmniSeq℠ Precision Medicine Technology, is featured as a “leading voice” in precision medicine.
Buffalo, NY – June 29, 2015—The digital publication Future of Personal Health focuses on precision medicine in an article entitled Precision Medicine: A Prescription for Better Prescribing (which also appeared as a print version in the June 26 edition of USA Today). The publication also features Dr. Carl Morrison, president and founder of OmniSeq as part of a digital panel of experts addressing the questions: How are patients being affected—and what’s at stake for physicians?
The panel interview, entitled Curbing Cancer with More Precise Treatment (Q&A), asks several leading voices in the industry to speculate on the future of this rapidly advancing technology.
In the article, Dr. Morrison predicts: “In the next 10 years personalized medicine will be the standard of care in clinical practice across many disease states including oncology, cardiovascular disease, and diabetes.”
About OmniSeq, LLC
OmniSeq, LLC was established in June 2015 as a for-profit company created from the Center for Personalized Medicine at Roswell Park Cancer Institute (RPCI). OmniSeq offers a suite of innovative products that support a physician-driven, collaborative approach to genomic diagnostics for cancer. The OmniSeq℠ Precision Medicine Technology platform provides institutions with the first-ever fusion of clinical genomics and a comprehensive information technology solution that delivers easy access to actionable insights about a patient’s tumor genetics and available treatment options. Headquartered in Buffalo, New York, OmniSeq offers services in the United States. For more information or to join the genomic network, call 1-800-781-1259 or visit www.omniseq.com.